文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

透明细胞肾细胞癌中预后标志物及过氧化物酶体相关关键基因的鉴定与实验验证

Identification and Experimental Validation of Prognostic Signature and Peroxisome-Related Key Genes in Clear Cell Renal Cell Carcinoma.

作者信息

Fan Congcong, Li Yifei, Zhang Weizhi, Wang Yining, Li Yanzhen, Zheng Jianjian, Yu Zhixian, Guo Yong

机构信息

Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.

Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.

出版信息

Int J Gen Med. 2025 May 23;18:2687-2702. doi: 10.2147/IJGM.S513102. eCollection 2025.


DOI:10.2147/IJGM.S513102
PMID:40433044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12109615/
Abstract

INTRODUCTION: Clear cell renal cell carcinoma (ccRCC) is a common urological malignant tumor. Dysregulated peroxisomes contribute to the progression of cancers. However, the prognostic significance of peroxisome-related genes (PGs) in ccRCC is still poorly understood. METHODS: PGs were collected from MsigDB. Prognostic differentially expressed genes were filtered via differentially expression analysis and univariate Cox regression analysis. The construction of risk model was performed by the least absolute shrinkage selection operator Cox regression analysis. Subsequently, the clinical application of risk model in prognosis prediction, tumor microenvironment (TME) and drug sensitivity was comprehensively evaluated. The expression levels of genes were measured by qRT-PCR and immunohistochemistry. Finally, the role of the genes of this risk model in biological behaviors of RCC cells was further verified via CCK-8, transwell invasion and wound healing assay. RESULTS: A risk model, including 9 PGs, was established. The risk model exhibited a robust and accurate performance in prognostic prediction across TCGA, GSE167573 and the local cohorts. Moreover, the risk model was closely correlated with clinical characteristics, TME and drug sensitivity. Silencing of the key genes attenuated the proliferation, migration, and invasion ability of RCC cells. CONCLUSION: The novel peroxisome-related risk model holds promise as a prognostic tool for estimating the prognosis of ccRCC patients and provides insights into treatment strategies.

摘要

引言:透明细胞肾细胞癌(ccRCC)是一种常见的泌尿系统恶性肿瘤。过氧化物酶体失调会促进癌症进展。然而,过氧化物酶体相关基因(PGs)在ccRCC中的预后意义仍知之甚少。 方法:从MsigDB中收集PGs。通过差异表达分析和单变量Cox回归分析筛选预后差异表达基因。采用最小绝对收缩选择算子Cox回归分析构建风险模型。随后,全面评估风险模型在预后预测、肿瘤微环境(TME)和药物敏感性方面的临床应用。通过qRT-PCR和免疫组织化学检测基因表达水平。最后,通过CCK-8、Transwell侵袭和伤口愈合试验进一步验证该风险模型的基因在肾癌细胞生物学行为中的作用。 结果:建立了一个包含9个PGs的风险模型。该风险模型在TCGA、GSE167573和本地队列的预后预测中表现出强大而准确的性能。此外,风险模型与临床特征、TME和药物敏感性密切相关。关键基因的沉默减弱了肾癌细胞的增殖、迁移和侵袭能力。 结论:新的过氧化物酶体相关风险模型有望作为评估ccRCC患者预后的预后工具,并为治疗策略提供见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/a523a97ee2d9/IJGM-18-2687-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/e689f86ff016/IJGM-18-2687-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/05956c77866f/IJGM-18-2687-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/42b8229f677f/IJGM-18-2687-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/e5c9c83b4326/IJGM-18-2687-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/64246d283eb0/IJGM-18-2687-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/84996047e5fd/IJGM-18-2687-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/530735c42c6a/IJGM-18-2687-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/6c66626f5089/IJGM-18-2687-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/a523a97ee2d9/IJGM-18-2687-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/e689f86ff016/IJGM-18-2687-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/05956c77866f/IJGM-18-2687-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/42b8229f677f/IJGM-18-2687-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/e5c9c83b4326/IJGM-18-2687-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/64246d283eb0/IJGM-18-2687-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/84996047e5fd/IJGM-18-2687-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/530735c42c6a/IJGM-18-2687-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/6c66626f5089/IJGM-18-2687-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73c9/12109615/a523a97ee2d9/IJGM-18-2687-g0009.jpg

相似文献

[1]
Identification and Experimental Validation of Prognostic Signature and Peroxisome-Related Key Genes in Clear Cell Renal Cell Carcinoma.

Int J Gen Med. 2025-5-23

[2]
Identification of HDAC10 as a candidate oncogene in clear cell renal carcinoma that facilitates tumor proliferation and metastasis.

Diagn Pathol. 2024-9-5

[3]
Exploration of a prognostic signature for mitochondria-related genes and the therapeutic prospects of vorinostat in clear cell renal cell carcinoma.

Transl Androl Urol. 2025-2-28

[4]
Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients.

Front Oncol. 2020-5-5

[5]
Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.

J Cancer Res Clin Oncol. 2023-10

[6]
A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma.

J Transl Med. 2025-2-27

[7]
The Expression and Prognostic Value of Co-stimulatory Molecules in Clear Cell Renal Cell Carcinoma (CcRcc).

Comb Chem High Throughput Screen. 2024

[8]
Construction and validation of a prognostic model for predicting clear cell renal cell carcinoma based on complement-related genes.

Transl Androl Urol. 2023-4-28

[9]
Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.

Transl Androl Urol. 2023-4-28

[10]
Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.

Transl Androl Urol. 2025-4-30

本文引用的文献

[1]
NIPAL4 is an important marker for clear cell renal cell carcinoma prognosis and immunotherapy.

Sci Rep. 2025-3-26

[2]
Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.

BMC Cancer. 2025-1-27

[3]
AXL: shapers of tumor progression and immunosuppressive microenvironments.

Mol Cancer. 2025-1-11

[4]
Oxidative Stress and Cancer Therapy: Controlling Cancer Cells Using Reactive Oxygen Species.

Int J Mol Sci. 2024-11-18

[5]
CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets.

JACS Au. 2024-5-14

[6]
Macrophage-Derived Nanosponges Adsorb Cytokines and Modulate Macrophage Polarization for Renal Cell Carcinoma Immunotherapy.

Adv Healthc Mater. 2024-8

[7]
Characterization and validation of fatty acid metabolism-related genes predicting prognosis, immune infiltration, and drug sensitivity in endometrial cancer.

Biotechnol Appl Biochem. 2024-8

[8]
Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma.

Cancer Res. 2024-5-15

[9]
A prognostic metabolism-related gene signature associated with the tumor immune microenvironment in neuroblastoma.

Am J Cancer Res. 2024-1-15

[10]
CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α.

Cell Death Dis. 2024-1-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索